Cohance Lifesciences Q4 FY26 Results: PAT Rs 19.55 Crore

Cohance Lifesciences Q4 FY26 results were announced on 12 May 2026, with the company reporting a consolidated net profit of Rs 19.55 crore for the quarter ended March 31, 2026. The Cohance Lifesciences Q4 FY26 performance will be assessed by investors against the broader macro backdrop of India’s economic recovery, sectoral dynamics in CDMO and API, and management commentary on the FY27 outlook.

Click Here – Get Free Investment Predictions

Cohance Lifesciences reported a consolidated Q4 FY26 PAT decline to Rs 19.55 crore, reflecting the operational challenges in the CDMO and API segment during the March quarter. The company is building its CDMO capabilities and contract pipeline for FY27 growth.

Cohance Lifesciences Q4 FY26 Key Financial Highlights

The following table summarises key Cohance Lifesciences Q4 FY26 financial highlights as reported on 12 May 2026.

Parameter	Q4 FY26	Reference
Net Profit (PAT)	Rs 19.55 crore	Prior year period
NSE Ticker	COHANCE	Sector: CDMO and API

Screen the best stocks on the Univest Screener.

Cohance Lifesciences Q4 FY26 Profit Analysis

Cohance Lifesciences Q4 FY26 net profit of Rs 19.55 crore reflects the company’s quarterly performance in CDMO and API. The decline was driven by cost pressures, competitive dynamics, and sector-specific headwinds that management will address in FY27. Investors will closely monitor management commentary on margin trajectory and FY27 guidance from these Cohance Lifesciences Q4 FY26 results.

The Q4 FY26 performance places Cohance Lifesciences among the companies facing near-term headwinds in the CDMO and API sector for the March 2026 quarter. The company operates in CDMO and API, a sector that is closely watched for demand trends, margin recovery, and volume growth in the context of India’s overall economic momentum in FY27.

Revenue and Operating Performance in Cohance Lifesciences Q4 FY26

The revenue performance in Cohance Lifesciences Q4 FY26 reflects the operating dynamics of the CDMO and API sector during the January to March 2026 quarter. The Cohance Lifesciences Q4 FY26 operating performance will be evaluated against the context of broader industry trends, raw material costs, and demand conditions in the company’s key markets.

Management commentary on volume growth, pricing power, margin trajectory, and order book position will be key inputs for analysts revising their FY27 estimates following these Cohance Lifesciences Q4 FY26 results.

Cohance Lifesciences Q4 FY26 Stock Price and Market Position

Cohance Lifesciences is listed on the NSE under the ticker COHANCE and operates in the CDMO and API sector. Following the Cohance Lifesciences Q4 FY26 results announcement on 12 May 2026, the stock will be assessed by the market based on the quarterly profitability trajectory, management commentary on FY27 outlook, and dividend decision. Investors should track live price movements and analyst rating changes on the Univest Screener.

Cohance Lifesciences FY27 Outlook

Post Cohance Lifesciences Q4 FY26 results, the key areas of investor focus for FY27 include management’s guidance on revenue growth, operating margin trajectory, capital expenditure plans, and demand visibility in the CDMO and API sector. Management’s roadmap for margin recovery and demand normalization in FY27 will be critical for investor confidence. The broader macroeconomic backdrop of India’s continued growth momentum, RBI rate cuts, and sectoral policy tailwinds will also shape the FY27 earnings outlook for Cohance Lifesciences.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on Cohance Lifesciences Q4 FY26 Results

What is Cohance Lifesciences Q4 FY26 net profit?

Ans. Cohance Lifesciences Q4 FY26 consolidated net profit is Rs 19.55 crore.

When did Cohance Lifesciences announce Q4 FY26 results?

Ans. Cohance Lifesciences announced Q4 FY26 results on 12 May 2026, through a board meeting held on the same date, with filings submitted to BSE and NSE thereafter.

What was Cohance Lifesciences revenue in Q4 FY26?

Ans. Cohance Lifesciences Q4 FY26 financial results were filed with BSE and NSE on 12 May 2026. Track live data on the Univest Screener.

What is the FY27 outlook for Cohance Lifesciences?

Ans. Post Q4 FY26 results, investors will closely monitor management guidance on revenue growth, margin trajectory, and capital allocation in the CDMO and API sector for FY27.

Where can I track Cohance Lifesciences Q4 FY26 live price?

Ans. Track Cohance Lifesciences live price, analyst ratings, and Q4 FY26 earnings updates on the Univest Screener for real-time data and research.

Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. All financial data cited is sourced from BSE/NSE exchange filings and verified news sources. Investments in securities are subject to market risk. Consult a SEBI-registered investment advisor before making any investment decision.